This week, the House Ways and Means Committee in Congress will consider the Build Back Better Agenda, part of which would change the Orphan Drug Tax Credit (ODTC) in ways that would severely undercut the original goal of the 1983 Orphan Drug Act. NORD is deeply concerned about this and we need your help!
The 1983 Orphan Drug Act is crucial to the rare disease community because it encourages innovation for the more than 90% of rare diseases that lack a Food and Drug Administration (FDA) approved treatment.
Please ask your members of Congress to maintain this critical incentive and ensure more rare disease patients can one day can have access to an FDA approved drug.
Together we are strong,
The NORD Policy Team
The Rare Action Network® is powered by NORD, the leading non-profit organization serving the rare disease community through programs of advocacy, education, research and patient services.
NORD, a 501(c)(3) organization, is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them. NORD, along with its more than 300 patient organization members, is committed to the identification, treatment and cure of rare disorders through programs of education, advocacy, research, and patient services. www.rarediseases.org